Maximal Extension Interval and Visual Outcomes in a Treat-and-Extend Protocol: A Post-Hoc Analysis of the CANTREAT Randomized Trial
Conclusion: The capacity to extend does not necessarily associate with improved visual acuity outcomes, with the poorest change in BCVA see n in those extended 8-10 weeks. The highest change in BCVA and lowest decrease in CRT was in the group maximally extended for 4 weeks. There was a correlation between change in BCVA and change in CRT for other extension groups. Future studies should establish the predictive factors for successful ex tension in patients undergoing TE in nAMD.
Source: Ophthalmologica - Category: Opthalmology Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Canada Health | Clinical Trials | Lucentis | Opthalmology | Ranibizumab Injection | Statistics | Study | Vitamin A